Caladrius Biosciences, Inc. (CLBS) Rating Increased to Buy at Zacks Investment Research
Caladrius Biosciences, Inc. (NASDAQ:CLBS) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a report released on Tuesday. The firm currently has a $4.25 target price on the biotechnology company’s stock. Zacks Investment Research‘s target price would indicate a potential upside of 12.73% from the stock’s current price.
According to Zacks, “Caladrius Biosciences, Inc. is an immunotherapy company which specializes in cell process optimization, development and manufacturing. Its product candidate consists of NBS20, a targeted cancer immunotherapy product for the treatment of metastatic melanoma; NBS10, an ischemic repair product to preserve heart muscle function following an acute myocardial infarction and NBS03D, an immune modulation product for the treatment of diabetes which are in different clinical trials. Caladrius Biosciences, Inc., formerly known as NeoStem, Inc., is headquartered in New York. “
Several other equities research analysts also recently issued reports on the stock. HC Wainwright restated a “buy” rating and set a $7.00 price objective on shares of Caladrius Biosciences in a research report on Friday, July 21st. ValuEngine upgraded shares of Caladrius Biosciences from a “strong sell” rating to a “sell” rating in a research report on Friday, September 1st.
Caladrius Biosciences (CLBS) opened at 3.73 on Tuesday. Caladrius Biosciences has a 12-month low of $2.65 and a 12-month high of $7.79. The firm has a 50-day moving average price of $4.05 and a 200 day moving average price of $4.51.
Caladrius Biosciences (NASDAQ:CLBS) last issued its quarterly earnings data on Thursday, August 10th. The biotechnology company reported ($0.88) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.96) by $0.08. Caladrius Biosciences had a negative net margin of 84.10% and a negative return on equity of 180.68%. On average, equities research analysts predict that Caladrius Biosciences will post ($2.42) earnings per share for the current year.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Vanguard Group Inc. raised its position in shares of Caladrius Biosciences by 2.8% in the second quarter. Vanguard Group Inc. now owns 155,380 shares of the biotechnology company’s stock valued at $723,000 after buying an additional 4,163 shares in the last quarter. KCG Holdings Inc. raised its position in shares of Caladrius Biosciences by 74.6% in the first quarter. KCG Holdings Inc. now owns 36,291 shares of the biotechnology company’s stock valued at $183,000 after buying an additional 15,501 shares in the last quarter. Finally, Renaissance Technologies LLC raised its position in shares of Caladrius Biosciences by 34.3% in the first quarter. Renaissance Technologies LLC now owns 97,552 shares of the biotechnology company’s stock valued at $491,000 after buying an additional 24,900 shares in the last quarter. Institutional investors own 6.47% of the company’s stock.
Caladrius Biosciences Company Profile
Caladrius Biosciences, Inc is a cell therapy development company with product candidates in development based on multiple technology platforms and targeting autoimmune and cardiology indications. The Company’s lead product candidate, CLBS03, is a T regulatory cell (Treg) clinical Phase II therapy targeting adolescents with recent-onset type 1 diabetes mellitus (T1DM) using the patient’s own numerically and functionally enhanced Tregs.
Receive News & Stock Ratings for Caladrius Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Caladrius Biosciences Inc. and related stocks with our FREE daily email newsletter.